GlassScriptPhysician profile
Bryan Patrick Fink
NPI 1568952869
$1,317.69
in general payments reported to CMS, 2019-2025
11 companies · $899 in 2025
The $899 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23.43 · 2021: $8.32 · 2022: $295 · 2024: $91.55 · 2025: $899.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $531 · Food and Beverage: $410 · Long Term Medical Supply Or Device Loan: $49.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $531.13 |
| Food and Beverage | $409.92 |
| Long Term Medical Supply Or Device Loan | $49.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Solventum Corporation | $856.13 | 2025 | 3m Cavilon, Kerramax Care, Activ.A.C. |
| Novo Nordisk INC | $148.49 | 2022 | |
| Glaxosmithkline, LLC. | $98.69 | 2022 | |
| Abbott Laboratories | $49.95 | 2024 | Freestyle Insulinx |
| Amgen INC. | $47.76 | 2022 | |
| Surgenex LLC | $26.08 | 2025 | Renograft, Surgraft, Ardeograft |
| Amarin Pharma, INC. | $23.43 | 2019 | |
| Boston Scientific Corporation | $21.90 | 2024 | Watchman Access System |
| Smith+Nephew, INC. | $19.70 | 2024 | Collagenase Santyl |
| Lilly USA, LLC | $17.24 | 2025 | Mounjaro, Zepbound |
| Organon LLC | $8.32 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Fink listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.